Lantern Pharma has launched a new artificial intelligence (AI)-powered module to improve the precision, cost and timelines of antibody-drug conjugates (ADCs) development for cancer.
The Nasdaq-listed AI company is advancing the application of its proprietary RADR AI platform, which leverages AI and machine learning (ML) to optimise ADC development.
According to Lantern Pharma, RADR AI utilises over 100 billion oncology data points and more than 200 advanced ML algorithms to address major challenges in oncology drug development.
Lantern Pharma said that it is advancing several ADC candidates through preclinical development.
The company is also collaborating with the MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany. Initially, this partnership will focus on synthesising and evaluating ADCs related to cryptophycins, a potent antitumor molecule.
Lantern Pharma’s lead development initiatives include a Phase 2 clinical programme and multiple Phase 1 trials.
Lantern Pharma CEO and president Panna Sharma said: “This breakthrough demonstrates how AI can transform the traditionally costly and time-consuming process of ADC development.
“By simultaneously analysing multiple data types and integrating mutation profiles with target expression, our team was able to identify optimal therapeutic combinations that have the potential to be more effective and safer for specific patient populations.”
In a peer-reviewed study, Lantern Pharma showcased the capabilities of its AI-driven RADR AI platform.
The research used the platform to analyse complex datasets, including transcriptomics, proteomics, and mutation profiles across 22 tumour types.
Key highlights of the AI-powered ADC module include the successful validation of the platform through the identification of 22 clinically proven targets with established therapeutic potential.
The platform also discovered 60 novel targets, presenting significant opportunities for new intellectual property development, portfolio expansion, and strategic licensing partnerships.
Additionally, the module developed proprietary mutation-specific targeting capabilities, enabling improved clinical trial design, more precise indication selection, and more accurate patient response predictions.
This framework is expected to reduce ADC development costs by up to 60% and expedite timelines by 30-50% for Lantern Pharma and its collaborators.
The RADR AI platform is said to offer a highly scalable, machine-learning-ready approach that can systematically evaluate thousands of potential tumour sub-types and indications.
Furthermore, the platform has created a clear pathway to commercialisation through industry partnerships and collaborative development programmes.
The AI company is continuing to enhance the precision and capabilities of RADR as part of its ongoing development.
